Generic placeholder image

Mini-Reviews in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1389-5575
ISSN (Online): 1875-5607

Current Strategies for the Development of Novel Antipsychotic Drugs

Author(s): Jordi Bolos

Volume 3, Issue 3, 2003

Page: [239 - 251] Pages: 13

DOI: 10.2174/1389557033488169

Price: $65

Abstract

While classical neuroleptics are characterized by dopamine D2 antagonism, this is also considered to be the cause of their neurological side effects. In recent years, novel antipsychotic drugs with improved efficacy, devoid of extrapyramidal effects are being developed. The mechanisms of action of these new atypical antipsychotics can be classified into three general groups: a) binding to D2 together with non-dopaminergic receptors, b) interaction with dopamine receptor subtypes other than D2 and c) selective binding to nondopaminergic systems, such as glutamatergic, sigma, neurotensin, and cannabinoid.

Keywords: Antipsychotic Drugs, D2 antagonism, dopamine receptor, neurotensin, glutamatergic, nondopaminergic


Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy